Medicinal application of medicinal salt or derivative of heparin and low molecular heparin

A low-molecular-weight heparin and medicinal salt technology, which is applied in the field of medicine, can solve the problems of diabetic patients' recovery and achieve rich therapeutic effects

Active Publication Date: 2009-11-25
LUNAN PHARMA GROUP CORPORATION
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although there are many kinds of oral hypoglycemic drugs on the market, so far, there is no drug that can make diabetic patients recover

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal application of medicinal salt or derivative of heparin and low molecular heparin
  • Medicinal application of medicinal salt or derivative of heparin and low molecular heparin
  • Medicinal application of medicinal salt or derivative of heparin and low molecular heparin

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0026] prescription

[0027] Low molecular weight heparin sodium 1000U

[0028] Microcrystalline Cellulose 50g

[0029] 8% hydroxypropyl methylcellulose solution appropriate amount

[0030] Low-substituted hydroxypropyl cellulose 30g

[0031] Magnesium Stearate 2.0g

[0032] Preparation process: Low-molecular-weight heparin sodium is passed through a 100-mesh sieve, microcrystalline cellulose and low-substituted hydroxypropyl cellulose are passed through a 80-mesh sieve, and the prescription amount of heparin sodium, low-substituted hydroxypropyl cellulose, and microcrystalline cellulose is mixed. Uniformly add 8% hydroxypropyl methylcellulose solution to granulate in an appropriate amount, dry at 60°C, sieve through a 16-mesh sieve, add prescription amount of magnesium stearate to the dry granules, mix evenly, and compress into tablets.

Embodiment 2

[0034] prescription

[0035] Calcium Heparin 14000U

[0036] 220g pregelatinized starch

[0037] Mannitol 200g

[0038] Lactose 150g

[0039] 6% PVP in 95% ethanol solution

[0040] Micronized silica gel 13g

[0041] Preparation process: pass the heparin calcium, pregelatinized starch, mannitol, lactose and micropowdered silica gel in the prescription through a 100-mesh sieve, mix well, add 6% PVP in 95% ethanol solution to granulate in appropriate amount, dry at 60°C, and dry for 18 Mesh sieve for granulation, then fill the capsules.

Embodiment 3

[0043] prescription

[0044] Low Molecular Heparin Calcium 5000U

[0045] Cross-linked sodium carboxymethyl starch 180g

[0046] Microcrystalline Cellulose 110g

[0047] Ethylcellulose 5g

[0048] Vitamin E 10g

[0049] Magnesium Stearate 3.5g

[0050] Preparation process: The sustained-release tablet can be prepared according to the preparation process of the sustained-release tablet.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
molecular weightaaaaaaaaaa
Login to view more

Abstract

The invention relates to an application of a medicinal salt or a derivative of heparin and low molecular heparin for preparing an oral medicament composition, belonging to the field of medicines. The oral medicament composition enables a diabetic to recover after long-time treatment of diabetes, can prevent a patient who has reduced sugar tolerance from becoming a diabetic and can improve the vitality of islet cell beta. The medicinal application of the medicinal salt or the derivative of the heparin and the low molecular heparin has significant treatment effect and is quite suitable for clinical application.

Description

technical field [0001] The invention belongs to the field of medicine, and in particular relates to the application of heparin, pharmaceutically acceptable salts of low-molecular-weight heparin or their derivatives in the preparation of a pharmaceutical composition, especially the application in the preparation of a medicine for curing diabetes patients. Background technique [0002] The incidence of diabetes is still increasing year by year. According to data, diabetes has become the fifth leading cause of death in the world, and is considered to be a non-communicable disease second only to cardiovascular and cerebrovascular diseases and malignant tumors. In 2005, the global diabetic population has expanded to 220 million people. At present, there are no less than 40 million diabetic patients in my country, and many patients are at risk of impaired glucose tolerance. In developing countries, including my country, the adult prevalence rate is relatively high, and the middle...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/727A61P3/10
Inventor 赵志全
Owner LUNAN PHARMA GROUP CORPORATION
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap